|
 |
| SHORT COMMUNICATION |
|
|
|
| Year : 2022 | Volume
: 54
| Issue : 5 | Page : 349-352 |
| |
Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience
Trupti Rekha Swain1, Siddhartha Goutam1, Rabindra Kumar Jena2, Niranjan Rout3
1 Department of Pharmacology, SCB Medical College, Cuttack, Odisha, India
2 Department of Clinical Haematology, SCB Medical College, Cuttack, Odisha, India
3 Acharya Harihar Regional Cancer Centre, Cuttack, Odisha, India
| Date of Submission | 30-Oct-2021 |
| Date of Decision | 03-Nov-2022 |
| Date of Acceptance | 16-Nov-2022 |
| Date of Web Publication | 13-Dec-2022 |
Correspondence Address:
Niranjan Rout
Acharya Harihar Regional Cancer Centre, Cuttack, Odisha
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.ijp_844_21
BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in CML patients in the chronic phase with imatinib (400 mg/day).
MATERIALS AND METHODS: This prospective, observational study was conducted from November 2011 to May 2015 on 310 patients presented to the Departments of Clinical Hematology and Pharmacology of SCB MCH, Cuttack, diagnosed with CML at chronic phase. Collected ADRs were entered in the ADR reporting form (PvPI) and were analyzed for causality and severity.
RESULTS: Anemia was the most common hematological ADR, whereas hyperpigmentation and nausea were the most common nonhematological ADRs reported. Maximum ADRs were mild to moderate and required no change in the treatment course.
CONCLUSION: The study revealed that imatinib mesylate, a well tolerated drug, has very few cases of severe ADRs in Indian patients at the chronic stable phase of CML.
Keywords: Adverse drug reactions, chronic myeloid leukemia, Eastern India, imatinib mesylate
How to cite this article:
Swain TR, Goutam S, Jena RK, Rout N. Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience. Indian J Pharmacol 2022;54:349-52 |
How to cite this URL:
Swain TR, Goutam S, Jena RK, Rout N. Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience. Indian J Pharmacol [serial online] 2022 [cited 2023 Jun 1];54:349-52. Available from: https://www.ijp-online.com/text.asp?2022/54/5/349/363400 |
| » Introduction | |  |
Chronic myeloid leukemia (CML) is the most common hematological malignancy encountered by Indians.[1] WHO has designated BCR-ABL as the defining abnormality in Philadelphia chromosome positive CML. BCR-ABL mutation happens when a peace of BCR & ABL genes break off and switch places. Imatinib mesylate is a revolutionary molecule that has significantly altered the management of CML in recent years.[2] At present, most Indian patients are receiving generic imatinib mesylate, either through the government supply portal or through the Glivec International Patient Assistance Program (GIPAP).[3] Due to the targeted therapy and the availability of multiple forms of the drug being utilized by our patients, it is possible that the molecule may show a different spectrum of adverse events in Indian patients. Hence, the present study aims to observe different short- and long-term adverse drug reactions (ADRs) to imatinib mesylate and to ascertain both causality and severity.
| » Materials and Methods | | |
Diagnosed patients of CML attending both the Outpatient Department and Indoor Clinical Hematology Department of SCB Medical College and Hospital, Cuttack, between November 2007 and May 2015 were included in the present study. Approval of the institutional ethics committee of SCB Medical College, Cuttack, was obtained before starting the study (IEC/IRB NO: 100). All the study participants provided written informed consent before inclusion in this study.
Inclusion criteria
Diagnosed adult patients (aged >18 years) of CML in the chronic phase were eligible for enrolment. Patients were considered new if the diagnosis is made for the first time and had not received any prior treatment related to CML.
Exclusion criteria
- CML in either accelerated phase/blast crisis
- Cardiac functional abnormality
- Impaired gastrointestinal (GI) function or any other serious medical conditions
- History of major surgery in the past 2 weeks
- History of taking medications having known interaction with imatinib.
Data collection and analysis
Patients were directly interviewed during their clinical visit and their case record sheets were reviewed for possible adverse reactions. Medication history was thoroughly asked and their physical, biochemical, and hematological parameters were recorded in the predesigned format. The data, thus, generated were analyzed regarding the severity of the reaction, the pattern of the reaction, and causality. All the collected ADRs were thoroughly analyzed by the causality assessment committee. The WHO-UMC Causality Assessment scale was used to reach the proper conclusion.[4] A modified Hartwig Siegel scale was used for determining the severity assessment of ADRs and was categorized as mild, moderate, and severe reactions.[5] Adverse events were monitored throughout the study treatment and for up to 28 days following the last dose of imatinib. ADRs were collected using a standard assessment form supplied by the Central Drugs Standard Control Organisation (CDSCO).[6] The data, thus, generated were entered into the MS Excel sheet and SPSS (IBM, SPSS statistics version, 20.0, Cal) was used for analyzing the data statistically.
Study design and treatments
This is a prospective, nonrandomized, open-label study. All eligible patients were evaluated as follows: general examination, systemic examination, routine complete blood count, and liver/kidney function test. Bone marrow examination was done in all the cases at the time of diagnosis for the proper staging of the disease. The diagnosis of CML was confirmed by the quantification of BCR-ABL byReverse Transcriptase - Polymerase Chain Reaction (RT-PCR) as per international scale. All patients in the chronic phase of CML have maintained 400 mg once daily of imatinib and they were followed up for 24 months. CML patients that required escalated doses of imatinib were excluded from the study. Patients with Grades 3 and 4 hematological ADRs and serious drug-related ADRs due to other factors were allowed for dose interruption.
| » Results | | |
Among 310 study participants included in the study, 239 (77%) were male and the rest 71 (23%) were female. At the time of diagnosis, the median age of our patients was 58 years (18–74 years). The median time for diagnosis in our patients was found to be 8 months (1–18 months). In our entire study period, a total of 1193 ADRs were observed in the study participants. Out of all, 509 (42.6%) were hematological and 684 (57.4%) were nonhematological. Anemia was found to be the most common among hematological ADRs followed by leukopenia. The maximum number of ADRs belonged to Grades 1 and 2 according to CTCAE (v4.03).[7] Furthermore, there was significantly less number of cases belonging to Grades 3 and 4 [Table 1].
The median onset lag in Grades 1 and 2 and Grades 3 and 4 were 12.5 and 17 weeks, respectively [Figure 1]. Out of nonhematological ADRs, hyperpigmentation was the most common, followed by pruritus and skin rash. The severe form of these reactions was significantly lower (except hypertension) as depicted in [Table 2]. When these cases were analyzed for causality assessment, the maximum cases belong to the possible category (54.7%), followed by certain (26.2%) and probable (19.1%) [Figure 2]. The severity of the observed ADRs by the modified Hartwig and Siegel scale showed that 51.6% of ADRs were mild, 38.6% were moderate, and 9.8% were severe in nature [Figure 3]. | Figure 1: Median duration of appearance of hematological ADRs from the beginning of the treatment with imatinib mesylate. ADRs: Adverse drug reactions
Click here to view |
 | Figure 2: Causality assessment of the observed ADRs. ADRs: Adverse drug reactions
Click here to view |
 | Figure 3: Severity assessment of the observed ADRs. ADRs: Adverse drug reactions
Click here to view |
| » Discussion | | |
Currently, imatinib mesylate is the first-line therapy for CML irrespective of the disease stage. Our study was conducted on 310 participants in the chronic phase of CML. The median age in our study is 58 years which is similar to some other studies conducted in India.[8],[9] Males were found to be more affected than females which corroborate with studies conducted by Bhatwadekar et al. and Deshmukh et al.[9],[10]
Although imatinib is a well-tolerated molecule, Grades 1 and 2 (mild to moderate) adverse events are quite common in patients who are treated with imatinib either for the treatment of CML or Philadelphia chromosome-positive ALL patients. In our study, after the hematological system, cutaneous ADRs were the second most common system to be affected. However, this manifestation was not totally similar to other studies.[12],[13],[14],[15] This might be due to genetic variation or environmental factors or the combined role of both components. Among hematological ADRs, anemia was the most common in our study which was in contrast to Meena et al. and Francis et al.[12],[15] However, the study by Abhijit et al. favors our study.[8] The median duration of the initiation of hematological ADRs was 12.5 and 17 weeks for Grades 1 and 2 and Grades 3 and 4, respectively, which was similar to the study by Meena et al.[15]
In this study, we found only 5% of all ADRs belong to Grades 3 and 4 hematological ADRs. In a significant percentage of chronic phases, CML patients experienced hematological toxicity from the administration of imatinib at the same dose (400 mg) in the IRIS trial. However, in Grades 3 and 4, hematological toxicity was observed in fewer patients. In another Chinese study conducted on CML patients treated with imatinib in the chronic phase, thrombocytopenia was noticed in maximum patients (21.8%), followed by Grades 3 and 4 neutropenia in17.8% and anemia in only 5.9% patients as hematological ADRs. (Li Zhou et al.).[16]
In the present study for the first time, we report a sizable number of patients having hyperpigmentation. Although it had been found by other studies, the frequency of occurrence is quite high.[11] “Imatinib targets the ATP binding site of the tyrosine kinases of the C-kit. It is now clear that basal cells and melanocytes of the skin have C-kit as normal expression.”[17] Few studies have suggested that “C-kit and its ligand stem cell factor have a major role in melanogenesis, melanocyte homeostasis, and Ultra Violet-B (UVB)-induced pigmentation.”[18] The role of imatinib in hyperpigmentation was also observed in the management of GI stromal tumors.[19],[20] There might be some photosensitivity reaction occurring in our study group that requires further in-depth analysis.
In this study, the maximum number of ADRs was mild in nature and only 9.8% were severe as per the severity scale. Imatinib was found to be the possible cause of the reaction in most of our CML patients as per the WHO Causality Assessment scale. Our study findings regarding causality and severity of reactions match with the observations done by Francis et al.[13]
| » Conclusion | | |
After the arrival of imatinib, CML treatment has found a new direction. The success rate of imatinib is way more than any of the chemotherapeutic agents and with a significantly lower frequency of severe ADRs. Thus, ensuring adherence in the initial management of CML should be our main strategy in the management of CML in Indian patients.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| » References | | |
| 1. | Ganesan P, Kumar L. Chronic myeloid leukemia in India. J Glob Oncol 2017;3:64-71.  |
| 2. | Sacha T. Imatinib in chronic myeloid leukemia: An overview. Mediterr J Hematol Infect Dis 2014;6:e2014007. |
| 3. | Tekinturhan E, Audureau E, Tavolacci MP, Garcia-Gonzalez P, Ladner J, Saba J. Improving access to care in low and middle-income countries: Institutional factors related to enrollment and patient outcome in a cancer drug access program. BMC Health Serv Res 2013;13:304. |
| 4. | |
| 5. | Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32. |
| 6. | |
| 7. | Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Ver. 4.0. 2009. Available from: http://www.meddramsso.com. [Last accessed on 2021 Aug 29]. |
| 8. | Phukan A, Mandal PK, Dolai TK. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: Sharing experience of a hemato-oncology center from eastern India. Ann Hematol 2021;100:85-96. |
| 9. | Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, non-randomized study. J Assoc Physicians India 2005;53:291-5. |
| 10. | Bhatwadekar SS, Deshpande SV, Mehta A, Shah P. Efficacy and safety of generic imatinib compared to glivec in chronic phase – Chronic myeloid leukemia-single center retrospective analysis. Blood 2019;134 Suppl_1:4162. |
| 11. | O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. |
| 12. | Francis J, Palaniappan M, Dubashi B, Pradhan SC, Chandrasekaran A. Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study. J Pharmacol Pharmacother 2015;6:30-3. [ PUBMED] [Full text] |
| 13. | Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: Long-term considerations. Arch Toxicol 2012;86:1-12. |
| 14. | Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. |
| 15. | |
| 16. | Li Z, Jianxiang W, Xiaojun H, Jianda H, Zhixiang S. Preliminary comparison of the efficacy and safety of dasatinib and imatinib in the treatment of newly diagnosed chronic myelogenous leukemia. Chin J Hematol 2013;34:93-7. Available from: http://rs.yiigle.com/zhxyxzz20133402/396221.html. [Last accessed on 2021 Aug 29]. |
| 17. | Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-25. |
| 18. | Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8. |
| 19. | Rehman H, Hakim N, Sugarman R, Seetharamu N, Saif MW. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement. J Oncol Pharm Pract 2020;26:1511-5. |
| 20. | Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 2008;14:7. |
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]
|
